TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Acurx Pharmaceuticals ( (ACXP) ) is now available.
On September 16, 2025, Acurx Pharmaceuticals held a special meeting where shareholders approved the issuance of shares underlying series G-2 warrants and an increase in authorized shares. These approvals are significant for the company’s compliance with Nasdaq rules and could impact its market operations and shareholder value.
The most recent analyst rating on (ACXP) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.
Spark’s Take on ACXP Stock
According to Spark, TipRanks’ AI Analyst, ACXP is a Underperform.
Acurx Pharmaceuticals’ score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.
To see Spark’s full report on ACXP stock, click here.
More about Acurx Pharmaceuticals
Acurx Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and commercialization of new antibiotics for infections caused by bacteria, including resistant strains.
Average Trading Volume: 68,383
Technical Sentiment Signal: Sell
Current Market Cap: $6.53M
For detailed information about ACXP stock, go to TipRanks’ Stock Analysis page.